08.11.26 -- June 2026 — CDMO Opportunities And Threats Report

Platform-based manufacturing uses standardized, pre-qualified workflows and analytics that reduce variability, simplify regulatory submissions, and accelerate the path to commercial success.

Secure domestic or diversified biopharma manufacturing to protect therapeutic development from supply chain disruptions, rising costs, and legislative tariff impacts.

Operational excellence meets ethical stewardship. Data-driven strategies and renewable energy integration are shaping a responsible future for global manufacturing and community engagement.

Multi-continent manufacturing networks minimize supply chain risk. Relying on site alignment, robust tech transfer, and unified quality standards ensures a flexible and resilient supply chain.

Explore how reshoring, GLP-1 capacity demands, and integrated U.S.-based manufacturing models are reshaping CDMO partnerships in a rapidly evolving pharmaceutical market.

Rahul Purohit, Ph.D., discusses the challenges and opportunities of scaling non-viral gene-edited cell therapies, with practical guidance for balancing performance, cell quality, and manufacturing readiness.

ADC manufacturing requires specialized expertise, single‑use systems, precise filtration, aseptic filling, and integrated lyophilization to ensure stability, safety, and consistent clinical‑grade production.

See how polymorph screening with electron diffraction uncovers hidden forms, enabling precise identification and reliable quantification of minor phases affecting performance and manufacturability.

Biologics face unpredictable risks as complexity grows; evolving testing strategies to broaden detection, address gaps, and strengthen safety confidence without disrupting development or compliance.

An optimized lyophilization cycle removes excess moisture during scale‑up by adjusting drying for larger equipment, improving stability, maintaining efficiency, and supporting clinical validation.

Discover streamlined gene-to-IND development for early-stage NBE programs, delivering Phase I readiness through integrated services, rapid scale-up, transparent pricing, and coordinated execution.

Once you've identified a CMO partner, how do you ensure success? The secret: planning as early as possible – while your product is still in preclinical or clinical development.